Polymorphisms in NADPH oxidase CYBA gene modify the risk of ESRD in patients with chronic glomerulonephritis

Renal Failure

Volumn 38, Issue 2, 2016, Pages 262-267

  Zhou, Hui ^a   Chen, Min ^a   Zhu, Ying ^a   Wang, Bing ^a   Liu, Xiao Ning ^a   Zuo, Zhi ^b   Tang, Feng Ying ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b AFFILIATED ZHONGDA HOSPITAL OF SOUTHEAST UNIVERSITY   (China)

Author keywords

ESRD with chronic glomerulonephritis; Polymorphisms in NAPDH CYBA gene; SNPs

Indexed keywords

CHOLESTEROL; CREATININE; CYTOCHROME B; DNA; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TRIACYLGLYCEROL; CYBA PROTEIN, HUMAN;

ADULT; ARTICLE; CASE CONTROL STUDY; CHOLESTEROL BLOOD LEVEL; CHRONIC GLOMERULONEPHRITIS; CONTROLLED STUDY; CREATININE CLEARANCE; END STAGE RENAL DISEASE; ENZYME ACTIVITY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE MAP; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TRIACYLGLYCEROL BLOOD LEVEL; CHRONIC DISEASE; COMPLICATION; GENETICS; GLOMERULONEPHRITIS; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; RISK ASSESSMENT;

CASE-CONTROL STUDIES; CHRONIC DISEASE; FEMALE; GLOMERULONEPHRITIS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NADPH OXIDASE; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK ASSESSMENT;

EID: 84956958177     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2015.1117905     Document Type: Article

References (37)

1. Modaresi A, Nafar M, Sahraei Z. Oxidative stress in chronic kidney disease. Iran J Kidney Dis. 2015; 9: 165-179.
2. Fu XJ, Peng YB, Hu YP, et al. NADPH oxidase 1 and its derived reactive oxygen species mediated tissue injury and repair. Oxid Med Cell Longev. 2014; 2014: 282854.
3. Kim YW, Byzova TV. Oxidative stress in angiogenesis and vascular disease. Blood. 2014; 123: 625-631.
4. Guimarães-Souza NK, Yamaleyeva LM, Lu B. Superoxide overproduction and kidney fibrosis: A new animal model. Einstein (Sao Paulo). 2015; 13: 79-88.
5. Kuchta A, Pacanis A, Kortas-Stempak B, et al. Estimation of oxidative stress markers in chronic kidney disease. Kidney Blood Press Res. 2011; 34: 12-19.
6. Hacişevki A, Gönenç A, Sezer S, et al. Accumulation of an endogenous inhibitor of nitric oxide synthesis and oxidative DNA damage in end-stage renal disease. Clin Lab. 2013; 59: 1353-1361.
7. Sedeek M, Nasrallah R, Touyz RM, et al. NADPH oxidases, reactive oxygen species, and the kidney: friend and foe. J Am Soc Nephrol. 2013; 24: 1512-1518.
8. Popolo A, Autore G, Pinto A, et al. Oxidative stress in patients with cardiovascular disease and chronic renal failure. Free Radic Res. 2013; 47: 346-356.
9. Chen S, Meng XF, Zhang C. Role of NADPH oxidase-mediated reactive oxygen species in podocyte injury. Biomed Res Int. 2013; 2013: 839761.
10. Babior BM. NADPH oxidase. Curr Opin Immunol. 2004; 16: 42-47.
11. Bengtsson SH, Gulluyan LM, Dusting GJ, et al. Novel isoforms of NADPH oxidase in vascular physiology and pathophysiology. Clin Exp Pharmacol Physiol. 2003; 30: 849-854.
12. Lambeth JD. NOX enzymes and the biology of reactive oxygen. Nat Rev Immunol. 2004; 4: 181-189.
13. Nowak T, Niemiec P, Zak I. The p22phox protein and the CYBA gene. Their function and associations with atherosclerosis-related diseases. Wiad Lek. 2013; 66: 10-17.
14. de Oliveira Alvim R, Santos PC, Dias RG, et al. Association between the C242T polymorphism in the p22phox gene with arterial stiffness in the Brazilian population. Physiol Genomics. 2012; 44: 587-592.
15. Xu Q, Yuan F, Shen X, et al. Polymorphisms of C242T and A640G in CYBA gene and the risk of coronary artery disease: A meta-analysis. PLoS One. 2014; 9: e84251.
16. Tarazona-Santos E, Machado M, Magalhães WC, et al. Evolutionary dynamics of the human NADPH oxidase genes CYBB, CYBA, NCF2, and NCF4: Functional implications. Mol Biol Evol. 2013; 30: 2157-2167.
17. Castaldo SA, da Silva AP, Matos A, et al. The role of CYBA (p22phox) and catalase genetic polymorphisms and their possible epistatic interaction in cervical cancer. Tumour Biol. 2015; 36: 909-914.
18. Fan KL, Zhang HF, Zhu ZY, et al. Association of CYBA rs7195830 polymorphism with estimated glomerular filtration rate in an adult Han sample from Jiangsu province, China. Chin Med J (Engl). 2013; 126: 3311-3315.
19. Tang FY, Zhu Y, Wang. GH. Relation between development of cardiovascular disease and the C242T CYBA polymorphism of the NADPH oxidase in ESRD patients. Disease Markers. 2010; 29: 89-93.
20. Dias IH, Griffiths HR. Oxidative stress in diabetes-circulating advanced glycation end products, lipid oxidation and vascular disease. Ann Clin Biochem. 2014; 51: 125-127.
21. Mohar DS, Barseghian A, Haider N, et al. Atherosclerosis in chronic kidney disease: Lessons learned from glycation in diabetes. Med Clin North Am. 2012; 96: 57-65.
22. Youn JY, Siu KL, Lob HE, et al. Role of vascular oxidative stress in obesity and metabolic syndrome. Diabetes. 2014; 63: 2344-2355.
23. Brito R, Castillo G, González J, et al. Oxidative Stress in Hypertension: Mechanisms and Therapeutic Opportunities. Exp Clin Endocrinol Diabetes. 2015; 123: 325-335.
24. Krause M, Bock PM, Takahashi HK, et al. The regulatory roles of NADPH oxidase, intra-and extra-cellular HSP70 in pancreatic islet function, dysfunction and diabetes. Clin Sci (Lond). 2015; 128: 789-803.
25. Murdoch CE, Chaubey S, Zeng L, et al. Endothelial NADPH oxidase-2 promotes interstitial cardiac fibrosis and diastolic dysfunction through proinflammatory effects and endothelial-mesenchymal transition. J Am Coll Cardiol. 2014; 63: 2734-2741.
26. Zhang M, Perino A, Ghigo A, et al. NADPH oxidases in heart failure: Poachers or gamekeepers? Antioxid Redox Signal. 2013; 18: 1024-1041.
27. Holterman CE, Read NC, Kennedy CR. Nox and renal disease. Clin Sci (Lond). 2015; 128: 465-481.
28. Nabeebaccus A, Zhang M, Shah AM. NADPH oxidases and cardiac remodelling. Heart Fail Rev. 2011; 16: 5-12.
29. Bylund J, Brown KL, Movitz C, et al. Intracellular generation of superoxide by the phagocyte NADPH oxidase: how, where, and what for? Free Radic Biol Med. 2010; 49: 1834-1845.
30. Xaplanteris P, Vlachopoulos C, Baou K, et al. The effect of p22(phox) -930A/G, A640G and C242T polymorphisms of NADPH oxidase on peripheral and central pressures in healthy, normotensive individuals. Hypertens Res. 2010; 33: 814-818.
31. Liang B, Wei Q, Shen T, et al. The A640G polymorphism in the NAD(P)H oxidase p22phox gene (CYBA) is associated with risk reduction of coronary heart disease: A meta-analysis. Clin Biochem. 2014; 47: 409-416.
32. Izakovicova Holla L, Kanková K, Znojil V. Haplotype analysis of the NADPH oxidase p22 phox gene in patients with bronchial asthma. Int Arch Allergy Immunol. 2009; 148: 73-80.
33. Hoffmann M, Schirmer MA, Tzvetkov MV, et al. A functional polymorphism in the NAD(P)H oxidase subunit CYBA is related to gene expression, enzyme activity, and outcome in non-Hodgkin lymphoma. Cancer Res. 2010; 70: 2328-2338.
34. Schirmer M, Hoffmann M, Kaya E, et al. Genetic polymorphisms of NAD(P)H oxidase: variation in subunit expression and enzyme activity. Pharmacogenomics J. 2008; 8: 297-304.
35. de Boer M, de Klein A, Hossle JP, et al. Cytochrome b558-negative, autosomal recessive chronic granulomatous disease: Two new mutations in the cytochrome b558 light chain of the NADPH oxidase (p22-phox). Am J Hum Genet. 1992; 51: 1127-1135.
36. Doi K, Noiri E, Nakao A, Fujita T, et al. Haplotype analysis of NAD(P)H oxidase p22 phox polymorphisms in end-stage renal disease. J Hum Genet. 2005; 50: 641-647.
37. Wolf G, Panzer U, Harendza S, et al. No association between a genetic variant of the p22(phox) component of NAD(P)H oxidase and the incidence and progression of IgA nephropathy. Nephrol Dial Transplant. 2002; 17: 1509-1512.